Navigation Links
Medivation Presents New Data on Dimebon's Novel Mechanism of Action
Date:12/9/2008

al mechanism of action may account for the clinical benefit observed in the Dimebon Alzheimer's and Huntington's disease clinical trials completed to date.

About Dimebon

Dimebon is an oral small molecule in development with Pfizer for Alzheimer's and Huntington's diseases. It is currently being evaluated in a second pivotal Phase 3 trial in Alzheimer's disease. Results from the first pivotal trial were published in the July 19, 2008, edition of The Lancet. A Phase 2 study in Huntington's disease was recently completed, and further development is planned in Huntington's disease.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin next year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the mechanism of action of Dimebon, the p
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
2. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
3. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
4. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
5. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
7. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
8. Medivation Announces Participation in Upcoming Conferences
9. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
11. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to ... in Charlottetown , PEI.  Bioenterprise has ... Island ADAPT Council for the commercialization of agricultural technologies ... working with PEI ADAPT.  They have been at the ... a decade," explains Dave Smardon , President & ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 /PRNewswire/ ... and development of therapeutic antibodies, today announced ... (IL-36R) antibody program into IND-enabling studies. The ... a novel treatment for generalized pustular psoriasis ... high unmet medical need. ANB019 is wholly owned ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... June 9 to discuss the prevalence and prevention of NSAID-induced ... - , , BETHESDA, Md. and ... and Horizon Therapeutics, Inc. today launched Connect to Protect ... risks associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), ...
... week 26 in moderate to severe Crohn,s patients who ... CHICAGO, June 1 New data from the WELCOME ... meeting demonstrate that Cimzia(R) (certolizumab pegol) provides sustained symptom ... patients suffering from moderate to severe Crohn,s disease (CD) ...
... KVISTGAARD, Denmark, June 1 Detailed data from,a ... the,ASCO Annual Meeting in Orlando. The presentation was made by ... and the Dana-Farber Cancer,Institute who is also the principal investigator ... detailed analysis supports the headline data that were reported,in October ...
Cached Biology Technology:AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 2AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 2Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 4Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 5Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 6Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 7Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 8Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 9Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 10PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 2PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 3
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... -- IriTech, a leading iris based identity management technology ... Design Network, announced today that the Chief Minister ... MK2120U device during a launching event of Andhra Pradesh ... The iris scanner is manufactured by U.S. based ... India through its Indian partner, Biometronic Technology, ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... sea areas a serious ecological threat to the ... the environment, e.g. the increase of fish-eating animals ... One of the new guiding principles of political ... "ecosystems approach" should be used instead of traditional ...
... In the work defended at the University of the Basque ... cancer was created in order to reproduce the gene regulation ... as metastasis in the liver of patients. This in vitro ... identification of the origin of the factors regulating this expression, ...
... In the world of commercial materials, lighter and cheaper ... with superior strength and special properties, such as a ... been deformed by a physical or magnetic force. ,A ... has been developed by two research teams headed by ...
Cached Biology News:Fisheries should be regarded as a part of the maritime environment 2It is important to demonstrate the influence of the microenvironment in the process of metastasis 2It is important to demonstrate the influence of the microenvironment in the process of metastasis 3Metal foam has a good memory 2
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... SNP loci identification through targeting resequencing. ... design, intensive assay validation/optimization, high throughput ... or customer-supplied samples and sequence alignment ... for rapid and highly accurate identification ...
... Tissue Extract Protein Array Kit is designed ... extracts. The expression of a protein in ... specific antibody. When the antibody binds the ... sensitive chemiluminescent or fluorescent signal created by ...
... delivers enhanced statistics and statistical interpretation ... improvement managers. As an accepted organizational ... simplifies statistics for novice users and ... experts. It offers a powerful JMP ...
Biology Products: